Efficacy of Chemotherapy Regimens in Mantle Cell Lymphoma: A Single Center Experience

Authors : Mehmet Ali Aşık, Fahir Özkalemkaş, Vildan Ozkocaman

Pages : 411-417

Doi:10.32708/uutfd.1757844

View : 50 | Download : 142

Publication Date : 2025-12-08

Article Type : Research Paper

Abstract :This single-center study evaluates the clinical characteristics, treatment responses, and survival outcomes of patients with Mantle Cell Lymphoma (MCL). We retrospectively analyzed 25 patients with MCL treated at the Hematology Department of Bursa Uludag University between January 2000 and December 2014. The median follow-up was 37 months min-max=6-132). The cohort was predominantly male (84%), with 92% presenting with advanced-stage disease. The overall response rate to first-line chemotherapy was 72%, with 9 patients (36%) achieving complete remission. The median progression-free survival (PFS) was 17 months (range, 2–39), and the 3- and 5-year overall survival (OS) rates were 52% and 28%, respectively. Among nine patients requiring second-line therapy, three (33%) achieved partial remission, while three (33%) had no response; the remaining three patients died before response assessment. The median PFS with second-line treatment was 6 months. Seven (28%) patients underwent autologous hematopoietic stem cell transplantation (AHSCT). The AHSCT cohort was significantly younger (p=0.047) and demonstrated a significantly longer median OS (p<0.05) compared to non-transplanted patients. These real-life data confirm that despite therapeutic advances, MCL remains a challenging malignancy with poor outcomes after relapse.
Keywords : mantle hücreli lenfoma, kemoterapi, otolog hematopoietik kök hücre nakli

ORIGINAL ARTICLE URL